In short
Tepotinib is an investigational drug being studied in clinical trials for the treatment of various types of cancer, particularly non-small cell lung cancer (NSCLC) with specific genetic alterations. This article summarizes key findings from several clinical trials evaluating tepotinib's safety, efficacy, and pharmacokinetics in cancer patients and healthy volunteers. The trials explore tepotinib as both a monotherapy and in combination with other drugs for patients with MET gene alterations and other biomarkers.
At a glance
- Drug Name
- Tepotinib (also known as MSC2156119J)
- Primary Indications
- NSCLC with MET alterations, hepatocellular carcinoma, solid tumors with MET alterations
- Mechanism of Action
- MET kinase inhibitor
- Administration
- Oral, typically 500 mg daily
- Key Efficacy Measures
- Objective response rate, progression-free survival, overall survival
- Safety Assessments
- Adverse events, laboratory abnormalities, ECG changes, vital signs
- Combination Studies
- With osimertinib in EGFR-mutant NSCLC
- Biomarker Analyses
- MET amplification, MET exon 14 skipping mutations
- Quality of Life Measures
- EQ-5D-5L, EORTC QLQ-C30, NSCLC-SAQ
- Pharmacokinetic Studies
- Drug exposure, metabolism, drug-drug interactions
What is Tepotinib?
Tepotinib is a targeted cancer therapy drug. It is also known by other names such as MSC2156119J, EMD 1214063, and Tepmetko. Tepotinib belongs to a class of drugs called kinase inhibitors, which work by blocking specific proteins involved in cancer growth.
How Tepotinib Works
Tepotinib specifically targets and inhibits a protein called MET (Mesenchymal-epithelial Transition Factor). MET is involved in cell growth and survival. In some cancers, MET can be overactive or altered, leading to uncontrolled cell growth. By blocking MET, Tepotinib aims to slow down or stop the growth of cancer cells.
Conditions Treated with Tepotinib
Tepotinib is being studied and used to treat several types of cancer, including:
- Non-small cell lung cancer (NSCLC): Particularly in patients whose cancer has specific MET alterations, such as MET exon 14 skipping mutations or MET amplification.
- Hepatocellular carcinoma (HCC): This is a type of liver cancer.
- Other solid tumors: Tepotinib is being investigated for use in various other solid tumors that have MET alterations.
How Tepotinib is Administered
Tepotinib is typically given as an oral medication, meaning it is taken by mouth. The most common dosage studied in clinical trials is 500 mg once daily. However, the exact dosage may vary depending on the specific condition being treated and individual patient factors. Tepotinib is usually taken in cycles, with each cycle lasting 21 days.
Clinical Trials and Research
Tepotinib has been and continues to be studied in various clinical trials. Some key areas of research include:
- Efficacy in different cancers: Trials are evaluating how well Tepotinib works in treating different types of cancer, particularly those with MET alterations.
- Combination therapy: Some studies are looking at combining Tepotinib with other cancer drugs, such as osimertinib for certain types of lung cancer.
- Brain metastases: Research is being conducted on Tepotinib's effectiveness in treating cancer that has spread to the brain.
- Comparison with other treatments: Some trials are comparing Tepotinib to other standard treatments, such as sorafenib for liver cancer.
Potential Side Effects
Like all medications, Tepotinib can cause side effects. Common side effects reported in clinical trials include:
- Nausea and vomiting
- Diarrhea
- Fatigue
- Changes in liver function tests
- Changes in blood cell counts
More serious side effects can occur but are less common. It's important to discuss potential side effects with your healthcare provider.
Drug Interactions
Tepotinib may interact with other medications. One study specifically looked at how Tepotinib affects the metabolism of other drugs that are processed by a liver enzyme called CYP3A. This is important because many commonly used medications are processed by this enzyme. Your healthcare provider should be aware of all medications you're taking to avoid potential interactions.